Example: Heart Attack

Search clinical trials for: Modulation of FiO2

Total 10000 results

NCT04194359

Active, not recruiting

Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Microsatellite Stable | RAS Mutation
NCT04656067

Completed

Comparative Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate

Blood Loss, Surgical | Blood Loss, Postoperative
NCT04741165

Unknown

Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma
NCT01379274

Terminated

A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes

MDS
NCT02315625

Terminated

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Neuroendocrine Tumors | Carcinoma, Neuroendocrine | Neuroendocrine Carcinoma | Neuroendocrine Neoplasms | Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas
NCT01005472

Completed

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

Metastatic Melanoma
NCT00436332

Completed

S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

Lung Cancer
NCT02488330

Completed

An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study

Solid Tumor
NCT01209442

Completed

Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme

Glioblastoma Multiforme
NCT00829647

Withdrawn

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

Leukemia | Chronic Lymphocytic Leukemia
NCT01164189

Completed

Bevacizumab in Recurrent Grade II and III Glioma (TAVAREC)

Central Nervous System Tumors
NCT00453895

Completed

Sunitinib in Refractory Adrenocortical Carcinoma (SIRAC)

Adrenocortical Carcinoma
NCT00890929

Completed

Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Adult Acute Myeloblastic Leukemia
NCT02805426

Completed

Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage

Postpartum Hemorrhage
NCT01784978

Terminated

Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer (SUNRISES)

Metastatic Renal Cell Carcinoma
NCT00519896

Completed

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Cancer | Thyroid Gland Medullary Carcinoma | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid Cancer
NCT00583427

Withdrawn

Sulodexide Treatment in Patients With Dense Deposit Disease

Dense Deposit Disease
NCT01818973

Unknown

Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer

Rectal Cancer
NCT00416494

Completed

Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Colorectal Cancer
NCT00268359

Completed

Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas

Brain and Central Nervous System Tumors
NCT01368848

Completed

Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)

NSCLC
NCT01910142

Completed

Effect of Nutrition on Bone Metabolism as Assessed by 41Ca

Osteoporosis
NCT00501891

Completed

Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma

Glioblastoma Multiforme
NCT00006003

Terminated

SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated

Recurrent Melanoma | Stage IV Melanoma
NCT00027677

Completed

Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
NCT00130520

Completed

Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer

Ovarian Neoplasms
NCT00113529

Completed

Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell
NCT01144988

Unknown

Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma (AVIRMA01-09)

Recurrent Malignant Glioma
NCT00317200

Completed

A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer

Small Cell Lung Cancer
NCT00372567

Terminated

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor
NCT00463073

Completed

Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas

Malignant Gliomas
NCT00099970

Completed

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

Melanoma | Metastases
NCT00116506

Completed

Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer

Neoplasm Metastasis | Colorectal Cancer
NCT07128251

Not yet recruiting

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC) | Immunotherapy | PD-1 | TACE | CTLA-4
NCT06958484

Not yet recruiting

Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence

Adjuvant Treatment | HCC - Hepatocellular Carcinoma
NCT06878196

Not yet recruiting

ctDNA-guided First-line Immuno-de-escalation Therapy for IVB-stage and Recurrent Cervical Cancer

Uterine Cervical Neoplasm
NCT06856187

Recruiting

Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer (TASBEL)

Metastatic Colorectal Cancer (CRC)
NCT06423144

Not yet recruiting

PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7

Hepatocellular Carcinoma
NCT06408623

Not yet recruiting

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

Liver Cancer
NCT06035133

Not yet recruiting

Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy

Rectal Cancer
NCT05640609

Recruiting

Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer

Stomach Neoplasm
NCT05569681

Recruiting

Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients

Morbid Obesity
NCT04781270

Recruiting

mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Liver Metastases | Colorectal Carcinoma
NCT04699214

Recruiting

Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment

Other Disorders of Soft Tissues
NCT07075562

Completed

TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion

Hepatocellular Carcinoma (HCC)
NCT04667910

Completed

601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

Central Retinal Vein Occlusion
NCT07013812

Completed

Tranexamic Acid to Reduce Blood Loss in Women Having Planned Cesarean Section

Cesarean Section | Blood Loss During Surgery
NCT02397954

Completed

A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Idiopathic Polypoidal Choroidal Vasculopathy
NCT03772613

Completed

The Randomized OPTIMAL-ACT Trial

Coronary Artery Disease | Ischemic Heart Disease | Anticoagulant-induced Bleeding | Coronary Syndrome
NCT05690191

Enrolling by invitation

Chidamide in Patients With Recurrent and Refractory Diffuse Large b

Diffuse Large B-cell Lymphoma

Search clinical trials for: Modulation of FiO2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations